Cyntellect's products support applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells.
Missing: Cyntellect's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cyntellect's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cyntellect
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cyntellect is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Cyntellect has filed 1 patent.
Drug discovery, Clusters of differentiation, Transcription factors, Biotechnology, Molecular biology
Drug discovery, Clusters of differentiation, Transcription factors, Biotechnology, Molecular biology
Latest Cyntellect News
Apr 13, 2021
Chelmsford, Massachusetts, UNITED STATES CHELMSFORD, Mass., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Brooks Automation, Inc. (Nasdaq:BRKS), a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy, today announced that it had completed the acquisition of the Celigo® Cell Cytometer product line from Cyntellect Inc., a privately held life sciences Company based in San Diego. Introduced to the market in early 2010, Celigo has become one of the most rapidly adopted cell imaging systems based on its unique combination of high-throughput, ease-of-use, and affordability. The installed customer base for Celigo includes many of the top pharmaceutical, biotechnology, and academic institutions worldwide. As part of the transaction, the majority of Cyntellect's employees who have supported Celigo since inception are being moved to Brooks' nearby facility in Poway, CA, providing for a seamless transition of the key engineering, manufacturing, and R&D capabilities, as well as the field based sales and support personnel. Dr. Steve Schwartz, President and CEO of Brooks, stated, "The Celigo cellular imaging product line is an impressive addition to our family of stand-alone instrumentation products used by many of our automated sample management system life sciences customers. It joins a growing portfolio of high productivity automated solutions for the analysis, handling and testing of biological and compound samples prior to and following their storage in our automated sample management systems." Dr. Schwartz continued, "The Celigo cell cytometer enables microplate-based high-throughput, high-content, brightfield and fluorescence cellular imaging and analysis, with minimal sample manipulation." Saiid Zarrabian, President and CEO of Cyntellect, stated, "We are thrilled to have found a tremendous partner in Brooks to take Celigo to the next level. When combined with Brooks' world-class infrastructure, global commercial reach and worldwide customer support, Celigo will have the opportunity to penetrate markets that otherwise weren't accessible to Cyntellect. We are confident that Celigo's rapid early market penetration will be greatly accelerated by Brooks." The purchase price was disclosed as up to approximately $9.2 million with settlement of part of the purchase price deferred for a six month period. About Brooks Automation, Inc. Brooks is a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, we have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; we have expanded our reach to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe and Asia. For more information, please visit www.brooks.com . "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934 Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include statements regarding future adoption of new technologies and our ability to develop further our business. Factors that could cause results to differ from our expectations and other risks that we have identified are described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release. Mot-clé
Cyntellect Frequently Asked Questions (FAQ)
When was Cyntellect founded?
Cyntellect was founded in 1997.
Where is Cyntellect's headquarters?
Cyntellect's headquarters is located at 6620 Mesa Ridge Road, San Diego.
What is Cyntellect's latest funding round?
Cyntellect's latest funding round is Series E - III.
How much did Cyntellect raise?
Cyntellect raised a total of $42.6M.
Who are the investors of Cyntellect?
Investors of Cyntellect include Third Security, Sigma-Aldrich, Sumitomo Corporation, Bru II Venture Capital Fund, Iceland Genomics Ventures and 3 more.
Who are Cyntellect's competitors?
Competitors of Cyntellect include TransMedics, Affectiva, Senseonics, Posit Science, Corpora Systems and 9 more.
Compare Cyntellect to Competitors
Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.
Founded in 2004, PinPointe USA, Inc. is a privately held, emerging medical technology with headquarters in Chico, California.
AdviTech, Inc offers physiological-centric solutions to the impairments of Spatial Disorientation, Vertigo and Motion Sickness, commonly experienced in the environments of aviation, vehicular travel, and recreation. With Phase I and Phase II clinical studies completed through grants from The National Institute of Health, and technical research supported by a Texas-based university, AdviTech aims to offer a non-invasive, non-drug solution to a highly motion intolerant society.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Biophan is dedicated to providing technologies that offer innovative andcompetitive advantages to the medical device industry. The Company ishelping to commercialize the Myotech Circulatory Support System, which has potential to improve the treatment of acute heart failure.Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan istraded on the OTC market under the symbol BIPH, and is also listed on theFrankfurt Stock Exchange under the symbol BTN.
The company are a enterprise recognized in the enteral products industry as a manufacturer of high quality, yet cost-effective devices. The company supply products to domestic and international customers. The company also are a contract manufacturer focused on the development and production of equipment for the medical and life sciences industries. The company's organization is composed of individuals with years of industry experience. OST Medical has a strong commitment to the company's customers and the company are confident in the company's ability to meet customer expectations in quality, price and delivery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.